La Jolla Pharmaceutical (NASDAQ:LJPC) – SunTrust Banks issued their FY2022 earnings per share (EPS) estimates for shares of La Jolla Pharmaceutical in a research note issued on Tuesday. SunTrust Banks analyst Y. Suneja anticipates that the biopharmaceutical company will earn $3.75 per share for the year. SunTrust Banks has a “Buy” rating and a $65.00 price target on the stock.

Several other research firms have also recently commented on LJPC. Zacks Investment Research raised shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Wednesday, November 1st. HC Wainwright lifted their target price on shares of La Jolla Pharmaceutical from $62.00 to $91.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. BidaskClub cut shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Chardan Capital reaffirmed a “buy” rating and issued a $90.00 target price on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. Three analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $57.14.

La Jolla Pharmaceutical (NASDAQ:LJPC) traded up $2.02 during mid-day trading on Wednesday, reaching $30.20. 557,140 shares of the company’s stock traded hands, compared to its average volume of 681,301. The stock has a market cap of $668.79, a PE ratio of -5.92 and a beta of 1.63. La Jolla Pharmaceutical has a 12-month low of $16.71 and a 12-month high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.05.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its holdings in shares of La Jolla Pharmaceutical by 11.6% in the 2nd quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 462 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in shares of La Jolla Pharmaceutical by 20.4% in the 2nd quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 1,688 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of La Jolla Pharmaceutical by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,397 shares of the biopharmaceutical company’s stock valued at $399,000 after purchasing an additional 2,162 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of La Jolla Pharmaceutical by 23.0% in the 2nd quarter. Wells Fargo & Company MN now owns 16,937 shares of the biopharmaceutical company’s stock valued at $504,000 after purchasing an additional 3,167 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of La Jolla Pharmaceutical by 21.2% in the 2nd quarter. New York State Common Retirement Fund now owns 18,300 shares of the biopharmaceutical company’s stock valued at $545,000 after purchasing an additional 3,199 shares during the last quarter.

In related news, COO Jennifer Carver purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, December 27th. The shares were bought at an average price of $33.22 per share, for a total transaction of $33,220.00. Following the acquisition, the chief operating officer now directly owns 4,500 shares in the company, valued at $149,490. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Laura L. Douglass sold 10,000 shares of La Jolla Pharmaceutical stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $32.32, for a total transaction of $323,200.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at approximately $193,920. The disclosure for this sale can be found here. 25.47% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/18/la-jolla-pharmaceutical-ljpc-forecasted-to-earn-fy2022-earnings-of-3-75-per-share.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.